These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9653895)

  • 1. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
    Alegret M; Verd JC; Díaz C; Hernández G; Adzet T; Sánchez RM; Laguna JC
    Eur J Pharmacol; 1998 Apr; 347(2-3):283-91. PubMed ID: 9653895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.
    Verd JC; Peris C; Alegret M; Díaz C; Hernández G; Vázquez M; Adzet T; Laguna JC; Sánchez RM
    Br J Pharmacol; 1999 Jul; 127(6):1479-85. PubMed ID: 10455299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs.
    Suzuki H; Yamazaki H; Aoki T; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2001 Jan; 51(1):38-45. PubMed ID: 11215324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
    Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
    Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
    Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H
    Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
    Stein DT; Devaraj S; Balis D; Adams-Huet B; Jialal I
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2026-31. PubMed ID: 11742880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
    Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
    Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced hepatic fatty acid oxidation and upregulated carnitine palmitoyltransferase II gene expression by methyl 3-thiaoctadeca-6,9,12,15-tetraenoate in rats.
    Willumsen N; Vaagenes H; Rustan AC; Grav H; Lundquist M; Skattebøl L; Songstad J; Berge RK
    J Lipid Mediat Cell Signal; 1997 Nov; 17(2):115-34. PubMed ID: 9459137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol-lowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice.
    Jiang C; Wang Q; Wei Y; Yao N; Wu Z; Ma Y; Lin Z; Zhao M; Che C; Yao X; Zhang J; Yin Z
    J Ethnopharmacol; 2015 Dec; 176():17-26. PubMed ID: 26477373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of simvaglyzin and atorvaglyzin on the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase in rat liver.
    Stakhneva EM; Vavilin VA; Ragino YI; Safronova OG; Shintyapina AB; Ivanova MV
    Bull Exp Biol Med; 2013 Nov; 156(1):63-5. PubMed ID: 24319730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ; Barrett PH; Huff MW
    J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase.
    Ståhlberg D; Reihnér E; Rudling M; Berglund L; Einarsson K; Angelin B
    Hepatology; 1995 Apr; 21(4):1025-30. PubMed ID: 7705775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes.
    Ståhlberg D; Angelin B; Einarsson K
    J Lipid Res; 1989 Jul; 30(7):953-8. PubMed ID: 2794793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.
    Aggarwal D; West KL; Zern TL; Shrestha S; Vergara-Jimenez M; Fernandez ML
    BMC Cardiovasc Disord; 2005 Sep; 5():30. PubMed ID: 16188040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
    Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bezafibrate on hepatic cholesterol metabolism.
    Ståhlberg D; Reihnér E; Ewerth S; Einarsson K; Angelin B
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S33-6. PubMed ID: 2044640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.
    Aviram M; Rosenblat M; Bisgaier CL; Newton RS
    Atherosclerosis; 1998 Jun; 138(2):271-80. PubMed ID: 9690910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.